We and others recently reported a distinct class of oncogenic fusions involving the RAS-GEF RASGRF1 in NSCLC, pancreatic ductal adenocarcinoma (PDAC), melanoma, and sarcoma19–21. Here, RASGRF1 is linked to melanoma.